Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Rituximab.

Tanya Doan¹, Elena Massarotti

¹Tufts-New England Medical Center, Boston, Massachusetts 02111, USA.

Drugs of Today (Barcelona, Spain : 1998)

|February 14, 2006

Summary

Rituximab, a CD20-targeting antibody, is effective for non-Hodgkin

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rationale and design of the rheumatoid arthritis non-responders to treatment (RANT) study: Use of a bioinformatics platform and "decentralized" clinical recruitment design.

Contemporary clinical trials·2025

Same author

Publisher Correction: Interferon subverts an AHR-JUN axis to promote CXCL13<sup>+</sup> T cells in lupus.

Nature·2024

Same author

Interferon subverts an AHR-JUN axis to promote CXCL13<sup>+</sup> T cells in lupus.

Nature·2024

Same author

Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study.

Journal of the American Heart Association·2024

Same author

Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.

Seminars in arthritis and rheumatism·2024

Same author

Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.

The Lancet. Rheumatology·2024

Area of Science:

Immunology
Oncology
Rheumatology

Background:

Rituximab is a chimeric monoclonal antibody targeting CD20 on B-cells.
It is the first approved antibody for non-Hodgkin's lymphoma treatment.
Its precise cellular mechanisms require further elucidation.

Purpose of the Study:

To review the literature on rituximab's use in various conditions.
To highlight its efficacy and safety in autoimmune diseases and lymphoma.

Main Methods:

Literature review of rituximab's therapeutic applications.
Summary of clinical data from studies in lymphoma and autoimmune diseases.

Main Results:

Rituximab demonstrates efficacy and a favorable safety profile in non-Hodgkin's lymphoma.
Therapeutic benefits are observed in autoimmune diseases involving B lymphocytes.

Conclusions:

Rituximab is a valuable therapeutic agent for non-Hodgkin's lymphoma.
Its application extends to managing selected autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.